Tirosint Cost in Nevada 2026: Cash Price, Insurance, and Cheaper Alternatives

What Does Tirosint Actually Cost in Nevada in 2026?

The average cash-pay price for Tirosint at Nevada retail pharmacies in 2026 sits at approximately $230 per month. That figure reflects the IBSA Pharma manufacturer list price and has held steady relative to 2025, with no major wholesale price adjustment announced as of mid-2025. Patients without insurance or with high-deductible plans feel this most acutely.

Tirosint (levothyroxine sodium) is an alcohol-free, dye-free, gelatin-capsule formulation of levothyroxine approved by the FDA under NDA 022211 [1]. The FDA label notes that this formulation eliminates several inactive ingredients present in standard tablets, which matters for patients with documented absorption problems or hypersensitivities [1]. Because the active molecule is identical to generic levothyroxine tablets, some payers argue substitution is appropriate. That argument fails clinically for certain patients, which is why the prescriber's documentation of medical necessity is the single most important cost-reduction tool available.

A 2014 study by Vita et al. published in Endocrine (N=42) compared Tirosint gel capsules to standard levothyroxine tablets in patients with gastric disorders. Patients on the gel-cap formulation achieved target TSH suppression with a statistically lower dose requirement (P<0.05), suggesting superior bioavailability in this population [2]. That bioavailability advantage is the clinical justification your prescriber should document when requesting a prior authorization (PA).

The American Thyroid Association's 2014 hypothyroidism guidelines state: "Levothyroxine is the standard of care for hypothyroidism treatment," and note that formulation-specific differences in bioavailability are "clinically relevant in patients with gastrointestinal disease" [3]. Citing this guideline in a PA letter materially improves approval odds with Nevada commercial insurers.

GoodRx and similar coupon aggregators list Tirosint at Nevada pharmacies for $170, $210 per 30-capsule fill depending on dose strength, which is below the list price but still high for a daily maintenance medication [4]. Applying the IBSA savings card on top of a coupon is not permitted simultaneously; patients must choose one discount pathway.

Does Nevada Medicaid Cover Tirosint?

Nevada Medicaid does not cover Tirosint as of 2026. The Nevada Division of Health Care Financing and Policy (DHCFP) Preferred Drug List (PDL) includes generic levothyroxine tablets as the covered thyroid replacement agent [5]. Tirosint is not listed as a preferred or non-preferred covered drug under the Nevada Medicaid PDL, and a prior authorization for brand-name Tirosint has a very low probability of approval under current policy.

Medicaid enrollees who genuinely cannot absorb standard levothyroxine tablets face a gap in coverage that the state PDL does not currently address. The practical path for these patients is a compounded levothyroxine preparation from a 503A pharmacy, discussed below, or a formal appeal supported by physician documentation of medical necessity and failure of the generic tablet.

Nevada Medicaid covers approximately 900,000 residents as of 2024 [6]. For this population, the cost barrier to Tirosint is effectively absolute without a successful appeal.

The Centers for Medicare and Medicaid Services (CMS) Medicaid Drug Rebate Program database confirms levothyroxine sodium tablets are classified as a covered outpatient drug, while specialty gel-cap formulations remain outside standard rebate classifications for most state PDLs [7]. That classification gap is why state programs consistently exclude Tirosint.

Which Commercial Insurance Plans Cover Tirosint in Nevada?

Commercial plan coverage varies widely. Tirosint appears on Tier 3 (non-preferred brand) or Tier 4 (specialty) formularies at the majority of Nevada commercial insurers, including plans offered through Nevada Health Link under the ACA marketplace [8]. A Tier 3 placement typically means a $60, $120 copay per 30-day supply before deductible is met.

UnitedHealthcare, Anthem Blue Cross Blue Shield of Nevada, and Health Plan of Nevada each manage formulary placement independently by plan year. Calling the number on the back of your insurance card and asking specifically for the formulary tier for NDC 24338-0[dose strength] is faster than navigating member portals.

Prior authorization is the norm, not the exception. Most Nevada commercial plans require documentation of at least one of the following: (a) TSH instability on generic levothyroxine tablets at a stable dose, (b) a diagnosed gastrointestinal condition affecting absorption (celiac disease, short bowel syndrome, bariatric surgery history), or (c) a documented allergy or intolerance to tablet inactive ingredients [9].

A 2020 analysis in Thyroid examined formulary access to branded levothyroxine preparations across U.S. commercial plans and found that only 31% of plans covered branded formulations without restriction [10]. Nevada's commercial market broadly reflects that national pattern.

Medicare Part D plans follow CMS formulary guidance. Tirosint appears on some Part D formularies in Nevada as a non-preferred brand with a Stage 3 copay averaging $95, $140 per fill. Patients in the Extra Help program (Low-Income Subsidy) pay reduced copays regardless of tier placement, typically $3.90, $9.85 per fill in 2026 [11].

Is Compounded Levothyroxine Legal in Nevada, and What Does It Cost?

Compounded levothyroxine gel capsules and liquid preparations are legal in Nevada through licensed 503A compounding pharmacies. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to prepare patient-specific compounded medications from bulk active pharmaceutical ingredients when a valid prescription exists [12]. Nevada's State Board of Pharmacy regulates these pharmacies and requires compliance with USP Chapter 795 standards for non-sterile compounding.

The practical cost is close to $0 per month when compounded through pharmacies that work with telehealth platforms or membership-based prescribing services. Some HealthRX-affiliated compounding partners in Nevada charge $0, $30/month for compounded levothyroxine gel caps depending on dose and supply volume.

The key distinction patients need to understand: 503A pharmacies compound for individual patients on a prescription-by-prescription basis. They are not 503B outsourcing facilities, which produce large batches for hospital systems. A 503A pharmacy in Nevada can legally compound levothyroxine gel capsules or liquid to match a specific patient's dose, but only with a valid prescription from a licensed prescriber [12].

Quality considerations are real. Compounded preparations lack the FDA's finished drug product review, and potency variation is a documented concern. A study published in JAMA Internal Medicine assessed compounded thyroid preparations and found meaningful dose-to-dose variability compared to FDA-approved products [13]. Patients switching to compounded levothyroxine should recheck TSH 6 to 8 weeks after initiation and at each dose change. The American Thyroid Association recommends TSH testing "at 6-week intervals until stable" after any formulation change [3].

Nevada has not enacted state-level restrictions on compounded levothyroxine beyond standard 503A federal compliance requirements. The Nevada Board of Pharmacy's current enforcement priority list does not include levothyroxine compounding as a restricted category [14].

How the IBSA Savings Card Works in Nevada

IBSA Pharma offers a co-pay savings card for commercially insured patients that can reduce the monthly cost of Tirosint to as low as $0. The card is not valid for patients covered by federal or state government insurance programs, including Medicare, Medicaid, TRICARE, or the VA [15]. This exclusion eliminates a large share of Nevada patients from eligibility.

For eligible patients, the mechanics work as follows. The prescriber sends a Tirosint prescription to any Nevada retail pharmacy that stocks the product. The patient enrolls in the IBSA savings program at TirosintDirectSavings.com or through the pharmacy counter. The savings card is applied at the point of sale, and IBSA subsidizes the difference between the patient's copay and the contracted rate up to the program cap, which has historically been $150 per fill [15].

Enrollment is online and takes under 5 minutes. No income verification is required for the commercial card. The card renews annually and must be re-activated each benefit year. Patients who switch insurance plans mid-year should re-confirm eligibility, because a government plan enrollment terminates card access immediately.

Cash-pay patients (no insurance at all) are not eligible for the co-pay card. Cash-pay patients should instead use GoodRx Gold or a similar discount program, which brings the Nevada price to approximately $170, $210 per fill, or pursue the compounded alternative described above.

How to Get Tirosint via Telehealth in Nevada

Telehealth prescribing of Tirosint is legal in Nevada. Nevada Revised Statutes Chapter 629 permits licensed physicians and advanced practice registered nurses (APRNs) to prescribe Schedule V and non-scheduled prescription medications via synchronous video consultation without requiring a prior in-person visit for most indications [16]. Hypothyroidism management falls within this framework.

A telehealth visit for thyroid care in Nevada typically covers: review of prior TSH and free T4 lab results, dose calculation, prescription transmission to a pharmacy of the patient's choice, and a follow-up plan. Most platforms complete the intake and prescribing workflow in one visit if lab work was done within the prior 6 months.

The Endocrine Society's 2016 clinical practice guideline on hypothyroidism states that initial therapy should begin at "1.6 mcg/kg/day" for most adults, with dose adjustments guided by TSH measured at 4, 8-week intervals [17]. Telehealth providers in Nevada follow this same dosing algorithm; the delivery mechanism (video vs. in-person) does not change the clinical protocol.

Patients without recent TSH labs can order them through direct-access laboratory services in Nevada. Quest Diagnostics and LabCorp both operate patient-pay collection sites in Clark County and Washoe County. A TSH panel typically costs $30, $50 without insurance through these direct-access channels [18].

Why Tirosint Costs More Than Generic Levothyroxine Tablets

Generic levothyroxine tablets cost $4, $12 per month at most Nevada pharmacies. Tirosint costs roughly 20 times more. The price gap exists because Tirosint is a patented formulation, not a chemically distinct molecule. IBSA holds formulation patents covering the gel-capsule delivery system, and no FDA-approved generic gel-cap equivalent has entered the market as of mid-2025.

The clinical rationale for paying the premium centers on bioavailability. Standard levothyroxine tablets require an acidic gastric environment for optimal dissolution. Patients with Helicobacter pylori infection, autoimmune atrophic gastritis, proton pump inhibitor (PPI) use, or bariatric surgery history may absorb tablet-form levothyroxine erratically [2]. The Vita et al. 2014 study showed that switching these patients to the gel-cap formulation produced TSH stabilization without dose escalation in 85.7% of cases within 12 weeks [2].

A separate 2018 study in Endocrine Practice (Cappelli et al.) examined levothyroxine dose requirements in patients on PPIs. Patients on omeprazole or pantoprazole required a mean daily dose 22 to 34 mcg higher than PPI-naive patients to maintain equivalent TSH control [19]. For a patient already on the highest available generic tablet dose, a formulation switch to gel cap may achieve target TSH without the risks associated with supratherapeutic dosing.

For patients without documented absorption concerns, generic levothyroxine tablets remain the evidence-supported, cost-appropriate first-line choice. The FDA's guidance on levothyroxine bioequivalence standards confirms that currently approved generic tablets meet the same 90 to 111% bioavailability confidence interval as brand-name products in the general population [20].

What Nevada Patients Pay Across All Scenarios: A Direct Comparison

The actual monthly cost of Tirosint or its alternatives depends entirely on insurance status and which discount pathway the patient pursues. The table below summarizes realistic 2026 out-of-pocket costs for a Nevada patient taking a standard 100 mcg once-daily dose.

| Scenario | Monthly Cost (approx.) | |---|---| | Cash pay, no discount | $230 | | Cash pay with GoodRx/coupon | $170, $210 | | Commercial insurance, Tier 3 copay | $80, $150 | | Commercial insurance + IBSA savings card | $0, $30 | | Nevada Medicaid | Not covered | | Medicare Part D, non-LIS | $95, $140 | | Medicare Part D, Extra Help (LIS) | $3.90, $9.85 | | 503A compounded gel cap (telehealth partner) | $0, $30 | | Generic levothyroxine tablet (any payer) | $4, $12 |

The steepest savings come from combining a commercial insurance plan with the IBSA savings card. The second-steepest come from compounded gel caps through a 503A partner. Cash-pay patients who do not qualify for the savings card and who lack absorption-related diagnoses should discuss whether the generic tablet meets their clinical needs before absorbing the full $230 monthly cost.

Lab Monitoring Costs Nevada Patients Should Anticipate

Starting or switching to Tirosint is not a one-time pharmacy transaction. TSH monitoring every 6 to 8 weeks during dose titration is standard practice [3][17]. Each TSH test at a Nevada outpatient lab costs $25, $75 cash pay or a standard office-visit copay if ordered through a physician.

The American Association of Clinical Endocrinologists (AACE) recommends that once a patient achieves a stable TSH in the reference range, annual monitoring is sufficient for most adults with primary hypothyroidism [21]. Patients with cardiac disease, pregnancy, or significant comorbidities may require more frequent testing.

Quest Diagnostics offers a patient-pay TSH test for approximately $34 through their QuestDirect portal as of 2025 [18]. LabCorp's equivalent is approximately $39. These direct-pay options bypass insurance and provide results within 24 to 48 hours, which pairs well with telehealth-managed thyroid care in Nevada.

Switching from Tirosint to Compounded Levothyroxine: What to Expect

Patients moving from Tirosint gel caps to 503A-compounded gel caps should expect a 6 to 8 week settling period before TSH reflects the new formulation's steady-state effect. Bioavailability differences between manufacturer lots of compounded products can be larger than those seen with FDA-approved products, so TSH measurement at 6 and 12 weeks post-switch is advisable [13].

Symptoms to report to the prescribing clinician during any formulation transition include: persistent fatigue, unexplained weight gain, palpitations, or tremor. These may signal under- or over-replacement even if the labeled dose matches the prior prescription.

Dose-for-dose substitution at 100 mcg Tirosint to 100 mcg compounded levothyroxine is the standard starting point. The prescriber may adjust after reviewing the first post-switch TSH. Patients should not attempt dose self-adjustment during the transition period [17].